Lilly Surges Past $800 Trillion Market Cap as Tirzepatide MASH Data Ignites a New Therapeutic Frontier

Jun 08, 2024 10:39 CST Updated 10:39

Eli Lilly

Global Pharmaceutical R&D and Production Company

Madrigal Pharmaceuticals

Developer of Fatty Liver Disease Treatment Drugs

Novo Nordisk

Insulin Developer and Manufacturer

Akero Therapeutics

Developer of Therapeutic Drugs for Metabolic Diseases

Inventiva Pharma

Small Molecule Therapy Developer

The GLP-1 field, as the "top stream" in the pharmaceutical market, attracts the attention of the industry with every move.

Recently, at the annual meeting of the European Association for the Study of the Liver (EASL), Eli Lilly and Company announced positive data from the Phase 2 clinical trial, SYNERGY-NASH, of its GLP-1 class drug Tirzepatide in treating patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH).

These data not only bring hope to MASH, a disease that currently has no FDA-approved treatment, but also significantly boost market confidence in Eli Lilly and Company. Driven by this positive news, the stock price of Eli Lilly and Company surged substantially this week, breaking through the 800 billion USD market capitalization mark and hitting a record high of 849.99 USD per share.

The significant rise in stock price reflects investors' optimistic expectations for Eli Lilly and Company's future development prospects.

Market analysts generally believe that if tirzepatide can continue to maintain such efficacy in subsequent clinical trials and ultimately gain FDA approval, it will become a new revenue growth point for Eli Lilly and Company, further solidifying its leadership position in the pharmaceutical industry. At the same time, it will also drive competition and development within the industry, compelling other companies to accelerate their R&D efforts and enhance the efficacy and safety of their own products in order to secure a place in the market.

Does Tirzepatide Cross Over to MASH?

Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a severe chronic liver disease that represents a progressive form of non-alcoholic fatty liver disease (NAFLD). MASH is characterized by abnormal accumulation of fat in the liver, accompanied by inflammation and hepatocyte injury, which may lead to further fibrosis, cirrhosis, and even liver cancer.

MASH is often closely associated with metabolic syndrome, including conditions such as obesity, hypertension, diabetes, and dyslipidemia. Approximately 5% of adults worldwide are affected by MASH, and in regions with higher prevalence rates of metabolic syndrome, such as obesity and type 2 diabetes, the incidence of MASH may be even higher.

Frost & Sullivan data shows that by 2030, the global NAFLD population is expected to reach 2.43 billion, with the number of MASH patients reaching 490 million, and the global market size for NASH drugs potentially surpassing $30 billion. This forecast has injected a strong boost into global pharmaceutical companies, prompting them to intensify their R&D efforts in the MASH field.

Due to the complex and not yet fully understood pathogenesis of MASH, pharmaceutical companies worldwide are conducting in-depth explorations from multiple potential therapeutic directions. In March this year, Madrigal Pharmaceuticals' thyroid hormone receptor β (THR-β) agonist Resmetirom took the lead, becoming the frontrunner in the market. Meanwhile, GLP-1 class drugs, known as the "cross-disciplinary wonder drug," have emerged as a surprising "dark horse" contender, showing remarkable potential in the MASH treatment field.

As a GLP-1/GIP dual receptor agonist, tirzepatide was initially approved by the U.S. Food and Drug Administration (FDA) in May 2022 for the treatment of type 2 diabetes under the brand name Mounjaro. Subsequently, in November 2023, tirzepatide received FDA approval for weight management under the brand name Zepbound.

Against this backdrop, the clinical research on tirzepatide has not ceased.

SYNERGY-NASH is a randomized, double-blind, and placebo-controlled study evaluating the efficacy and safety of tirzepatide in patients with histologically confirmed NASH and stage 2 or 3 fibrosis.

The study enrolled a total of 190 patients who were biopsy-proven to have MASH, with fibrosis stages F2 or F3, and a non-alcoholic fatty liver activity score (NAS) ≥4. They were randomly assigned in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of either tirzepatide (5mg, 10mg, or 15mg) or placebo for 52 weeks.

The results showed that, without worsening of MASH, the proportion of patients with ≥1-stage improvement in fibrosis was 29.7% in the placebo group, 54.9% in the 5mg group, 51.3% in the 10mg group, and 51.0% in the 15mg group (p<0.05). Additionally, 71.7% to 78.3% of patients in the three dose groups had a NAS score reduction of ≥2 points, compared to 36.7% in the placebo group.

The versatility of tirzepatide has attracted widespread attention in the medical field, bringing new exploration pathways and market prospects to the pharmaceutical industry. Industry opinions suggest that with the continuous advancement of clinical research, GLP-1 drugs are expected to become a new treatment option for MASH, offering new hope to patients.

MASH Ignites the "Golden Track"?

The positive results achieved in the SYNERGY-NASH clinical trial not only added a new highlight to tirzepatide but also posed certain market competition pressure on Madrigal Pharmaceuticals and its lead product Resmetirom.

On the morning of June 5th, Madrigal's stock price fell sharply during the early trading session, reflecting investors' concerns about this new competitive landscape. Although Resmetirom, as the first MASH treatment drug approved by the FDA, has a first-mover advantage in the market, the outstanding clinical trial results of tirzepatide may alter the future market dynamics.

The large patient population and the scarcity of treatment drugs have made MASH a golden track with significant growth potential in the eyes of many pharmaceutical companies.

To date, more than a hundred potential therapeutic targets for MASH are being actively developed or have entered clinical trial stages. These targets cover a variety of different biological pathways and mechanisms, including but not limited to THR-β agonists, GLP-1 receptor agonists, fibroblast growth factor 21 (FGF21) analogs, and peptide-based GLP-1/GCGR dual receptor agonists.

In addition to Resmetirom and tirzepatide, the main products for MASH indications in the late stage of development are:

Novo Nordisk's Semaglutide: As a GLP-1 receptor agonist, semaglutide was originally used to treat type 2 diabetes, but studies have shown that it demonstrates potential therapeutic effects in reducing liver fat content and improving liver fibrosis. The ongoing Phase III clinical trial aims to evaluate its efficacy and safety in patients with MASH.

Akero Therapeutics' Efruxifermin (EFX): As an FGF21 analog, Efruxifermin is currently being evaluated in Phase III clinical trials. FGF21 is a protein with protective effects on the liver, metabolic regulation, and inflammation reduction. By mimicking the action of this natural hormone, Efruxifermin may help improve liver health in patients with MASH.

Inventiva's Lanifibranor: This is a PPAR agonist that, despite the suspension of patient recruitment in Phase III clinical trials due to safety concerns, has shown potential in early studies to improve liver fibrosis in MASH patients.

The development of Chinese pharmaceutical companies in the MASH field is remarkable. ASC41, developed by Ascletis Pharma, showed a significant reduction in liver fat content in a 52-week interim study, demonstrating good efficacy and safety. In addition, domestic companies such as Zhenzhu Pharma, CTTQ Pharma, Ascletis Pharma, Yacai Pharma, and Terns Biopharma are actively making progress, with some of their products already entering the clinical trial stage.

Despite the challenges in the development of MASH drugs, the field of MASH treatment is gradually seeing a ray of hope as our understanding of disease mechanisms deepens and treatment methods continue to innovate. The positive results achieved by tirzepatide in the SYNERGY-NASH clinical trial have further heightened market expectations for MASH therapeutic drugs.

Competition between companies will not only accelerate the R&D process of new drugs but may also lead to more personalized and precise treatment options. With the completion of more clinical trials and the approval of new drugs, it is expected that the MASH treatment field will witness more breakthroughs and choices in the coming years.

Editor: Cheng Lin